Information updates

EpiPen® supply update

17 May 2018: 

EpiPen® 300mcg adrenaline (epinephrine) autoinjectors continue to be distributed each week via wholesalers to pharmacies. Mylan has recently introduced an EpiPen toll-free hotline 1800 931 625 for inquiries about supply.  If a pharmacy is out of stock the pharmacist should contact their wholesaler/s to obtain stock. If there are any problems they should phone 1800 931 625 (AU) or 0800 168 169 (NZ).

Whilst the use of an expired adrenaline autoinjector is not ideal, research suggests that recently expired devices retain potency. Therefore, if no other adrenaline autoinjector is available, use of a recently expired device to treat anaphylaxis is advised, as stated on the ASCIA website:

Due to safety concerns ASCIA does not recommend doctors, pharmacists and other health professionals to advise patients or their carers to learn to draw up adrenaline using an adrenaline ampoule, needle and syringe.  Whilst using a recently expired device is not ideal, this is a safer option for patients at risk of anaphylaxis, than using an adrenaline ampoule, needle and syringe. 

In the case of anaphylaxis, patients or their carers should follow instructions on their ASCIA Action Plan - Give EpiPen® and call an ambulance by phoning 000 (AU) or 111 (NZ). 

Patients and/or carers who require advice should contact the national patient support organisations, Allergy & Anaphylaxis Australia (phone 1300 728 000 or email This email address is being protected from spambots. You need JavaScript enabled to view it.) or Allergy New Zealand


Mod ASCIA Member
Donate to AIFA
go to NAS website
ASCIA Member Login
ASCIA Update

Information for the community about allergic diseases, immunodeficiencies and other immune diseases.
See latest edition here...
Join our mailing list:


ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Quick Links


ASCIA is a registered trademark of the Australasian Society of Clinical Immunology and Allergy. All content is subject to copyright for the Australasian Society of Clinical Immunology and Allergy. Read more...

The content for the website is developed and approved by ASCIA Committee and ASCIA Working Party Members. Read more...

Disclaimer I Privacy

The ASCIA website is intended for use by ASCIA members, health professionals and the general public. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

Sponsors | Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites. 

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.



This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information: verify here.